Bristol-Myers Squibb Company (BMY) Q2 2016 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 2.37%

Bristol Myers Squibb's earnings report showed a positive EPS surprise, indicating better-than-expected profitability. However, the stock fell by 2.37%, likely due to the absence of revenue figures and guidance, which left investors uncertain about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.69	N/A	+2.68%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management highlighted the positive EPS surprise as a sign of operational efficiency. However, they did not provide specific revenue guidance.

Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.

They emphasized their commitment to ongoing research and development.

Bristol Myers Squibb Beats on EPS, Stock Down 2.37%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 2.37%

Key numbers

Management commentary